Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01497652 · ClinicalTrials.gov registry record · Phase 4

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

A Phase 4 study of Parkinson's Disease, sponsored by Georgetown University.

Completed
Registry status
Phase 4
Development phase
34
Enrollment target
1
Study location

NCT01497652 is a Phase 4 study of Parkinson's Disease that has completed, run by Georgetown University. The registered enrollment target is 34 participants, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01497652, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Georgetown University.

COMPLETED
Registry status
Phase 4
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II \& III at the end of week 14.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Rasagiline
  • DRUG Rasagiline/Placebo

Study Locations (1)

District of Columbia

  • Georgetown University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2012-01
Est. Completion 2015-03
Phase Phase 4

Sponsor

Georgetown University

227 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01497652

The ClinicalTrials.gov registry entry for NCT01497652 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (95% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Rasagiline is the first listed.

NCT01497652 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01497652 about?

NCT01497652 is a clinical study titled "A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy". The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg...

What is the current status of trial NCT01497652?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2012-01. Estimated completion is 2015-03.

What conditions does trial NCT01497652 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT01497652?

The interventions under investigation include: Rasagiline (DRUG), Rasagiline/Placebo (DRUG).

Who is sponsoring clinical trial NCT01497652?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01497652 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.